October 10, 2009 Michael Kauffman 262 Arnold Road Newton, MA 02459 Dear Michael,Onyx Pharmaceuticals Inc • February 23rd, 2010 • Biological products, (no disgnostic substances)
As you know, Onyx Pharmaceuticals and Proteolix, Inc. have entered into an Agreement and Plan of Merger (the “Merger Agreement”). Onyx would like to offer you continued employment with Onyx contingent upon the successful closing of this Merger pursuant to the terms set forth in this offer letter agreement. If the Merger does not close for any reason, the offer set forth herein shall be null and void, and this offer letter agreement shall have no force or effect. Capitalized terms not otherwise defined in this offer letter shall have the same meanings set forth in the Merger Agreement.
LICENSE AND SUPPLY AGREEMENTLicense and Supply Agreement • February 23rd, 2010 • Onyx Pharmaceuticals Inc • Biological products, (no disgnostic substances) • New York
This License and Supply Agreement (this “Agreement”) is made this 12th day of October, 2005 (the “Effective Date”), by and between CyDex, Inc., a Delaware corporation with offices at 10513 W. 84th Terrace, Lenexa, Kansas 66214, (“CyDex”), and Proteolix, Inc., a Delaware corporation with offices at 225 Gateway Boulevard, South San Francisco, California 94080 (“Proteolix”).
